
Breast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Research To Practice | Oncology Videos
00:00
Second‑Line HR+ Options: PI3K/AKT
Rita Nanda reviews alpelisib, capivasertib and tolerability differences for PIK3CA/AKT-altered patients.
Play episode from 28:45
Transcript


